Page 114 - Read Online

West et al. Rare Dis Orphan Drugs J 2024;3:22 https://dx.doi.org/10.20517/rdodj.2023.61 Page 29 of 34

42. Terryn W, Vanholder R, Hemelsoet D, et al. Questioning the pathogenic role of the GLA p.Ala143Thr “mutation” in Fabry disease:
implications for screening studies and ERT. JIMD Reports; Berlin, Heidelberg: Springer; 2012, pp. 102-8. DOI
43. Nakao S, Kodama C, Takenaka T, et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal
variant” phenotype. Kidney Int 2003;64:801-7. DOI
44. Hasbal NB, Caglayan FB, Sakaci T, et al. Unexpectedly high prevalence of low alpha-galactosidase a enzyme activity in patients with
focal segmental glomerulosclerosis. Clinics 2020;75:e1811. DOI PubMed PMC
45. Mersher S, Fornoni A. Podocyte pathology and nephropathy - sphingolipids in glomerular diseases. Front Endocrinol 2014;5:127.
DOI PubMed PMC
46. Townsend RR, Orth RM, Clawson CM, Li SC, Li YT. Increased glycosphingolipid excretion associated with proteinuria. J Clin
Invest 1978;62:119-23. DOI PubMed PMC
47. West M, Cornish M, Auray-Blais C, Hyndman S, Finkle N. Urine Gb3 can be elevated in the absence of Fabry disease: implications
for disease screening. In: Canadian Society Nephrology Meeting, St. Johns NL, USA, 27-29 Apr 2012.
48. Ferraz MJ, Marques ARA, Appelman MD, et al. Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of
glycosphingoid bases during deficiency of glycosidases. FEBS Lett 2016;590:716-25. DOI
49. Shayman JA, Akira A. Drug induced phospholipidosis: an acquired lysosomal storage disorder. Biochim Biophys Acta
2013;1831:602-11. DOI PubMed PMC
50. Choung HYG, Jean-Gilles J, Goldman B. Myeloid bodies is not an uncommon ultrastructural finding. Ultrastruct Pathol
2022;46:130-8. DOI
51. Chong PF, Nakamura K, Kira R. Mulberries in the urine: a tell-tale sign of Fabry disease. J Inherit Metab Dis 2018;41:745-6. DOI
PubMed
52. Zhou LN, Dong SS, Zhang SZ, Huang LW, Huang W. Concurrent Fabry disease and immunoglobulin a nephropathy: a case report.
BMC Nephrol 2023;24:324. DOI PubMed PMC
53. Debiec H, Valayannopoulos V, Boyer O, et al. Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement
therapy: a need for tolerance induction therapy. J Am Soc Nephrol 2014;25:675-80. DOI PubMed PMC
54. Hunley TE, Corzo D, Dudek M, et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease.
Pediatrics 2004;114:e532-5. DOI
55. Linares D, Luna B, Loayza E, Taboada G, Ramaswami U. Prevalence of Fabry disease in patients with chronic kidney disease: a
systematic review and meta-analysis. Mol Genet Metab 2023;140:107714. DOI PubMed
56. Schiffmann R, Hughes DA, Linthorst GE, et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions
from a “Kidney disease: improving global outcomes” (KDIGO) controversies conference. Kidney Int 2017;91:284-93. DOI
57. Moiseev S, Tao E, Moiseev A, et al. The benefits of family screening in rare diseases: genetic testing reveals 165 new cases of Fabry
disease among at-risk family members of 83 index patients. Genes 2022;13:1619. DOI PubMed PMC
58. Connaughton DM, Kennedy C, Shril S, et al. Monogenic causes of chronic kidney disease in adults. Kidney Int 2019;95:914-28. DOI
PubMed PMC
59. Groopman EE, Marasa M, Cameron-Christie S, et al. Diagnostic utility of exome sequencing for kidney disease. N Engl J Med
2019;380:142-51. DOI
60. Jefferies JL, Spencer AK, Lau HA, et al. A new approach to identifying patients with elevated risk for Fabry disease using a machine
learning algorithm. Orphanet J Rare Dis 2021;16:518. DOI PubMed PMC
61. Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab 2017;122:19-27.
DOI PubMed
62. Chévrier M, Brakch N, Céline L, et al. Autophagosome maturation is impaired in Fabry disease. Autophagy 2010;6:589-99. DOI
63. Bertoldi G, Caputo I, Driussi G, et al. Biochemical mechanisms beyond glycosphingolipid accumulation in Fabry disease: might they
provide additional therapeutic treatments? J Clin Med 2023;12:2063. DOI PubMed PMC
64. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA
2008;105:2812-7. DOI PubMed PMC
65. Sanchez-Niño MD, Sanz AB, Carrasco S, et al. Globotriaosylsphingosine actions on human glomerular podocytes: implications for
Fabry nephropathy. Nephrol Dial Transplant 2011;26:1797-802. DOI
66. Eijk M, Ferraz MJ, Boot RG, Aerts JMFG. Lyso-glycosphingolipids: presence and consequences. Essays Biochem 2020;64:565-78.
DOI PubMed PMC
67. Nikolaenko V, Warnock DG, Mills K, Heywood WE. Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3
in Fabry disease. Hum Mol Genet 2023;32:2464-72. DOI PubMed PMC
68. van der Veen SJ, Sayed ME, Hollak CEM, et al. Early risk stratification for natural disease course in Fabry patients using plasma
globotriaosylsphingosine levels. Clin J Am Soc Nephrol 2023;18:1272-82. DOI PubMed PMC
69. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. J Am Soc Nephrol 2002;13 Suppl 2:S134-8. DOI
70. Rozenfeld PA, de Los Angeles Bolla M, Quieto P, et al. Pathogenesis of Fabry nephropathy: the pathways leading to fibrosis. Mol
Genet Metab 2020;129:132-41. DOI
71. Wanner C, Oliveira JP, Ortiz A, et al. Prognostic indicators of renal disease progression in adults with Fabry disease: natural history
data from the Fabry registry. Clin J Am Soc Nephrol 2010;5:2220-8. DOI PubMed PMC
72. Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in